17 May 2010

Holy Grail cancer vaccine that blasts tumours in weeks hailed as huge leap in fighting disease

Aumenta dimensioni testoDiminuisci dimensioni testo
'Holy Grail' cancer vaccine that blasts tumours in weeks hailed as huge leap in fighting disease. The treatment, which will be tested on British patients over the next few months, can reverse and even cure malignant melanoma, the most dangerous form of skin cancer

If it proves successful in large- scale trials, there are hopes that new forms could be developed to fight other forms of cancer, such as breast and prostate.

Experts say it may even stop people getting cancer in the first place.

Lead researcher Professor Lindy Durrant, of Nottingham University, said: 'This is huge. We could now have a vaccine that can target a tumour and kill it without damage to surrounding healthy tissues or cells. 'In the short term, this could cure some patients with the disease, and in the long term it could be used to prevent people developing it in the first place.'
Professor Karol Sikora, a leading cancer expert, said: 'This is a very clever vaccine and I believe it will increase the cure rate for patients in the future.' More than 10,000 people are diagnosed with malignant melanoma every year in Britain.
Numbers have quadrupled over the past 30 years as more people enjoy sunshine holidays abroad or use tanning booths.

The vaccine contains DNA and fragments of tumour. These activate only the specific immune cells which target melanoma.

Amy Dickenson had aggressive bone cancer but survived with the help of a cancer vaccine The treatment, developed by the company Scancell, will initially be given both to patients with advanced skin cancer which has spread to other parts of the body, and to those in the earlier stage of the disease. Trials will begin at hospitals in Manchester, Nottingham and Newcastle. If successful, the jab could be available within ten years.


(Daily Mail)

Read more

youris.com provides its content to all media free of charge. We would appreciate if you could acknowledge youris.com as the source of the content.